Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers.

Drewe J, Sieber CC, Mottet C, Wullschleger C, Larsen F, Beglinger C

Clinical pharmacology and therapeutics1 Apr 1999Cited by 6 (Europe PMC)

PMID10223779DOI10.1016/s0009-9236(99)70136-0PepBankPUB-10223779

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialPharmacokinetics
In healthy men, lanreotide showed linear pharmacokinetics.
In plain wordsIn healthy men, lanreotide showed linear pharmacokinetics.
Peptide
Lanreotide
Outcome
Not applicableLinear pharmacokinetics
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 100, and 200 microg/h · intravenousAs given in this study (human).
Source sentences
Summary
Lanreotide showed linear pharmacokinetics.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty healthy male subjects participated in 2 subsequent placebo-controlled, double-blind crossover studies.
Summary · context
The effects of 3 doses of lanreotide (50, 100, and 200 microg/h) were investigated on 24-hour intragastric acidity (study I), food-stimulated gallbladder contraction, and plasma cholecystokinin release (study II).
Report a problemFND-1022377901
02HumanNon-randomized trialEfficacy outcome
In healthy men, lanreotide raised median intragastric pH from 1.4+/-0.2 with placebo to 2.5+/-0.8 (P < .002).
In plain wordsIn healthy men, lanreotide at 50 microg/h raised stomach pH compared with placebo.
Peptide
Lanreotide
Outcome
IncreaseMedian intragastric pH
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
50 microg/h · intravenousAs given in this study (human).
Measurements
Median intragastric pH
1.4 pH
placebo; +/-0.2 as reported
Median intragastric pH
2.5 pH
lanreotide 50 microg/h; +/-0.8 as reported
Source sentences
Summary
It raised median intragastric pH significantly and in a dose-dependent manner: from 1.4+/-0.2 (placebo) to 2.5+/-0.8 (P < .002) during administration of 50 microg/h lanreotide
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty healthy male subjects participated in 2 subsequent placebo-controlled, double-blind crossover studies.
Summary · context
The effects of 3 doses of lanreotide (50, 100, and 200 microg/h) were investigated on 24-hour intragastric acidity (study I), food-stimulated gallbladder contraction, and plasma cholecystokinin release (study II).
Report a problemFND-1022377902
03HumanNon-randomized trialEfficacy outcome
In healthy men, lanreotide raised median intragastric pH to 3.2+/-0.7 versus placebo at 1.4+/-0.2 (P < .001).
In plain wordsIn healthy men, lanreotide at 100 microg/h raised stomach pH compared with placebo.
Peptide
Lanreotide
Outcome
IncreaseMedian intragastric pH
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 microg/h · intravenousAs given in this study (human).
Measurements
Median intragastric pH
1.4 pH
placebo; +/-0.2 as reported
Median intragastric pH
3.2 pH
lanreotide 100 microg/h; +/-0.7 as reported
Source sentences
Summary
It raised median intragastric pH significantly and in a dose-dependent manner: from 1.4+/-0.2 (placebo) to 2.5+/-0.8 (P < .002) during administration of 50 microg/h lanreotide, to 3.2+/-0.7 (P < .001) during 100 microg/h lanreotide, and to 4.3+/-0.7 (P < .001) during 200 microg/h lanreotide.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty healthy male subjects participated in 2 subsequent placebo-controlled, double-blind crossover studies.
Summary · context
The effects of 3 doses of lanreotide (50, 100, and 200 microg/h) were investigated on 24-hour intragastric acidity (study I), food-stimulated gallbladder contraction, and plasma cholecystokinin release (study II).
Report a problemFND-1022377903
04HumanNon-randomized trialEfficacy outcome
In healthy men, lanreotide raised median intragastric pH to 4.3+/-0.7 versus placebo at 1.4+/-0.2 (P < .001).
In plain wordsIn healthy men, lanreotide at 200 microg/h raised stomach pH compared with placebo.
Peptide
Lanreotide
Outcome
IncreaseMedian intragastric pH
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
200 microg/h · intravenousAs given in this study (human).
Measurements
Median intragastric pH
1.4 pH
placebo; +/-0.2 as reported
Median intragastric pH
4.3 pH
lanreotide 200 microg/h; +/-0.7 as reported
Source sentences
Summary
It raised median intragastric pH significantly and in a dose-dependent manner: from 1.4+/-0.2 (placebo) to 2.5+/-0.8 (P < .002) during administration of 50 microg/h lanreotide, to 3.2+/-0.7 (P < .001) during 100 microg/h lanreotide, and to 4.3+/-0.7 (P < .001) during 200 microg/h lanreotide.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty healthy male subjects participated in 2 subsequent placebo-controlled, double-blind crossover studies.
Summary · context
The effects of 3 doses of lanreotide (50, 100, and 200 microg/h) were investigated on 24-hour intragastric acidity (study I), food-stimulated gallbladder contraction, and plasma cholecystokinin release (study II).
Report a problemFND-1022377904
05HumanNon-randomized trialEfficacy outcome
In healthy men, lanreotide did not significantly inhibit gastrin secretion compared with placebo.
In plain wordsIn healthy men, lanreotide did not significantly reduce gastrin secretion compared with placebo.
Peptide
Lanreotide
Outcome
No significant changeGastrin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
50, 100, and 200 microg/h · intravenousAs given in this study (human).
Source sentences
Summary
However, no significant inhibition of gastrin secretion could be established.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty healthy male subjects participated in 2 subsequent placebo-controlled, double-blind crossover studies.
Summary · context
The effects of 3 doses of lanreotide (50, 100, and 200 microg/h) were investigated on 24-hour intragastric acidity (study I), food-stimulated gallbladder contraction, and plasma cholecystokinin release (study II).
Report a problemFND-1022377905
06HumanNon-randomized trialEfficacy outcome
In healthy men, all lanreotide doses completely inhibited postprandial gallbladder contraction compared with placebo.
In plain wordsIn healthy men, all lanreotide doses blocked gallbladder contraction after meals compared with placebo.
Peptide
Lanreotide
Outcome
DecreasePostprandial gallbladder contraction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
50, 100, and 200 microg/h · intravenousAs given in this study (human).
Source sentences
Summary
All doses completely inhibited postprandial gallbladder contraction.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty healthy male subjects participated in 2 subsequent placebo-controlled, double-blind crossover studies.
Summary · context
The effects of 3 doses of lanreotide (50, 100, and 200 microg/h) were investigated on 24-hour intragastric acidity (study I), food-stimulated gallbladder contraction, and plasma cholecystokinin release (study II).
Report a problemFND-1022377906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT02054637

Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

Universitair Ziekenhuis Brusseln = 10Apr 2014 to est. Apr 2016

Acid Reflux Esophagitis · Non-acid Reflux Esophagitis

Trial page ClinicalTrials.govUpdated 4 Feb 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.